Dermatitis
MONDO:0002406An inflammatory process affecting the skin. Signs include red rash, itching, and blister formation. Representative examples are contact dermatitis, atopic dermatitis, and seborrheic dermatitis.
Also known as: inflammation of skin, inflammation of the skin, inflammation of zone of skin, inflammatory skin disease, skin inflammation, zone of skin inflammation
1623 clinical trials for this condition and its sub-types, 65 tagged with Dermatitis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Dermatitis
-
Atopic eczema 467 trials · 480 incl. sub-types
3 sub-types
- Allergic contact dermatitis 10 trials Sub-types →
- Allergic urticaria 3 trials · 5 incl. sub-types Sub-types →
- Allergic cutaneous vasculitis 1 trial
-
Psoriasis 379 trials
3 sub-types
- Pustular psoriasis 6 trials · 39 incl. sub-types Sub-types →
- Guttate psoriasis 2 trials
- Psoriasis 2 0 trials
-
Urticaria 28 trials · 164 incl. sub-types
14 sub-types
- Angioedema 19 trials · 66 incl. sub-types Sub-types →
- Idiopathic urticaria 0 trials · 66 incl. sub-types Sub-types →
- Chronic urticaria 12 trials · 20 incl. sub-types Sub-types →
- Physical urticaria 3 trials · 15 incl. sub-types Sub-types →
- Cold urticaria 10 trials
- Allergic urticaria 3 trials · 5 incl. sub-types Sub-types →
- Drug rash with eosinophilia and systemic symptoms 5 trials
- Cutaneous mastocytosis 1 trial Sub-types →
- Urticaria, aquagenic 1 trial
- Urticaria, familial localized heat 1 trial
- Melkersson-Rosenthal syndrome 0 trials
- Autoimmune urticaria 0 trials
- Papular urticaria 0 trials
- Pruritic urticarial papules and plaques of pregnancy 0 trials
-
Skin infection 12 trials · 152 incl. sub-types
14 sub-types
- Tinea infection 1 trial · 116 incl. sub-types Sub-types →
- Scabies 12 trials Sub-types →
- Demodex folliculitis 5 trials
- Impetigo 5 trials Sub-types →
- Infection by Trypanosoma gambiense 3 trials
- Erysipelas 1 trial
- Pthirus pubis infestation 0 trials
- Cercarial dermatitis 0 trials
- Cutaneous diphtheria 0 trials
- Furunculosis 0 trials
- Gonococcal keratitis 0 trials
- Herpes simplex dermatitis 0 trials
- Herpes zoster dermatitis 0 trials Sub-types →
- Sycosis barbae 0 trials
-
Vitiligo 100 trials
3 sub-types
- Generalized vitiligo 16 trials
- Alopecia universalis onychodystrophy vitiligo 0 trials
- Trichrome vitiligo 0 trials
-
Dermatomyositis 81 trials · 100 incl. sub-types
11 sub-types
- Juvenile dermatomyositis 41 trials
- Anti-MDA5 dermatomyositis 3 trials
- Clinically amyopathic dermatomyositis 1 trial · 2 incl. sub-types Sub-types →
- Adermatopathic dermatomyositis 0 trials
- Adult dermatomyositis 0 trials
- Anti-Mi2 dermatomyositis 0 trials
- Anti-NXP2 dermatomyositis 0 trials
- Anti-SAE dermatomyositis 0 trials
- Anti-TIF1 dermatomyositis 0 trials
- Classical dermatomyositis 0 trials
- Neonatal dermatomyositis 0 trials
-
Acne 91 trials
1 sub-type
- Adult acne 0 trials
-
Autoimmune bullous skin disease 7 trials · 55 incl. sub-types
11 sub-types
- Pemphigus 20 trials · 27 incl. sub-types Sub-types →
- Bullous pemphigoid 18 trials
- Mucous membrane pemphigoid 5 trials · 9 incl. sub-types Sub-types →
- Acquired epidermolysis bullosa 3 trials
- Dermatitis herpetiformis 1 trial Sub-types →
- Pemphigoid 1 trial
- IgA pemphigus 0 trials
- Anti-p200 pemphigoid 0 trials
- Linear IgA Dermatosis 0 trials
- Paraneoplastic pemphigus 0 trials
- Subcorneal pustular dermatosis 0 trials
-
Lichen planus 19 trials · 47 incl. sub-types
11 sub-types
- Lichen planus, oral 30 trials
- Lichen planus pigmentosus 2 trials
- Atrophic lichen planus 1 trial
- Hypertrophic lichen planus 1 trial
- Actinic lichen planus 0 trials
- Annular atrophic lichen planus 0 trials
- Annular lichen planus 0 trials
- Bullous lichen planus 0 trials
- Lichen planus pemphigoides 0 trials
- Lichen planus, familial 0 trials
- Linear lichen planus 0 trials
-
Radiodermatitis 37 trials · 42 incl. sub-types
1 sub-type
- Photosensitivity disease 4 trials · 5 incl. sub-types Sub-types →
-
Contact dermatitis 9 trials · 24 incl. sub-types
4 sub-types
- Allergic contact dermatitis 10 trials Sub-types →
- Irritant dermatitis 9 trials Sub-types →
- Contact dermatitis due to nickel 1 trial
- Occupational dermatitis 1 trial
-
Lichen sclerosus et atrophicus 10 trials · 20 incl. sub-types
1 sub-type
- Vulvar lichen sclerosus 15 trials
-
Seborrheic dermatitis 15 trials
1 sub-type
- Seborrheic infantile dermatitis 0 trials
-
Neurodermatitis 10 trials
-
Folliculitis 1 trial · 8 incl. sub-types
4 sub-types
- Demodex folliculitis 5 trials
- Acne keloid 1 trial
- Eosinophilic pustular folliculitis 1 trial Sub-types →
- Sycosis barbae 0 trials
-
Neurotic excoriation 5 trials
-
Cutaneous vasculitis 4 trials · 5 incl. sub-types
1 sub-type
- Allergic cutaneous vasculitis 1 trial
-
Acanthosis nigricans 4 trials
2 sub-types
-
Acneiform dermatitis 4 trials
-
Hydroa vacciniforme 2 trials
1 sub-type
- Hydroa vacciniforme, familial 0 trials
-
Acrodermatitis 0 trials · 2 incl. sub-types
1 sub-type
- Acrodermatitis chronica atrophicans 2 trials
-
Exfoliative dermatitis 1 trial
-
Granuloma annulare 1 trial
-
Lipodermatosclerosis 1 trial
-
Parapsoriasis 0 trials · 1 incl. sub-types
3 sub-types
- Pityriasis lichenoides 1 trial Sub-types →
- Large plaque parapsoriasis 0 trials
- Small plaque parapsoriasis 0 trials
-
Porphyria cutanea tarda 0 trials · 1 incl. sub-types
3 sub-types
- Familial porphyria cutanea tarda 1 trial
- Hepatoerythropoietic porphyria 0 trials
- Sporadic porphyria cutanea tarda 0 trials
-
Dermatosis papulosa nigra 0 trials
-
Food dermatitis 0 trials
-
Granulomatous dermatitis 0 trials
-
Intertrigo 0 trials
-
Pityriasis rosea 0 trials
-
Spongiotic dermatitis 0 trials
Most studied deeper sub-types
-
New study tracks Real-World use of eczema drug abrocitinib
Disease control CompletedThis study follows 200 people aged 12 and older with moderate-to-severe eczema who are starting a new prescription of abrocitinib. Researchers will track how much their skin improves over 12 months using standard eczema severity scores. The goal is to see how well the drug works …
Sponsor: Pfizer • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New biologic drug aims to clear stubborn eczema in just 24 weeks
Disease control CompletedThis study tests whether lebrikizumab, an injectable biologic, can improve skin symptoms in adults and adolescents (aged 12 and older) with moderate-to-severe atopic dermatitis, also known as eczema. Participants receive lebrikizumab for 24 weeks, and doctors measure changes in e…
Phase 3 • Sponsor: Almirall, S.A. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Can a fatty acid cream heal damaged skin? new trial tests it
Disease control CompletedThis completed trial tested a cream made from a fatty acid called tripalmitoleoylglycerol in 46 adults with chronic dermatitis. Participants applied the cream or a placebo daily for 30 days. Researchers measured skin barrier function and symptom scores to see if the cream improve…
Sponsor: Shenzhen People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New eczema drug shows promise in 2-Year extension trial
Disease control CompletedThis study looked at the long-term safety and effectiveness of lebrikizumab for adults and teens with moderate-to-severe atopic dermatitis (eczema). Participants who completed a previous year-long study could join this 2-year extension. The main goal was to see how many people st…
Phase 3 • Sponsor: Almirall, S.A. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Could a common arthritis drug tame rare immune disease Flare-Ups?
Disease control CompletedThis study tested the drug tofacitinib (Xeljanz) in 10 adults with chronic granulomatous disease (CGD) who had ongoing inflammation in the gut, skin, or lungs. Participants took the pill daily for 3 months to see if it was safe and could help control symptoms. The goal was to fin…
Phase 1/2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New pill shows promise for tough eczema in small study
Disease control CompletedThis study tested an experimental oral drug called ATI-2138 in 14 adults with moderate to severe atopic dermatitis (eczema). Participants took the pill twice daily for 12 weeks. Researchers tracked safety, side effects, and skin improvement using standard eczema scores. The goal …
Phase 2 • Sponsor: Aclaris Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New eczema drug shows promise in Long-Term safety trial
Disease control CompletedThis study tested the long-term safety and effectiveness of lebrikizumab, a drug for moderate-to-severe atopic dermatitis (eczema). Over 1,100 participants who had already taken the drug in earlier studies were followed for up to 33 months. The goal was to see how well the drug c…
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New drug camoteskimab tested for Tough-to-Treat eczema
Disease control CompletedThis study tested a new drug, camoteskimab, in 62 adults with moderate to severe eczema (atopic dermatitis). Participants received either the drug or a placebo for 16 weeks, followed by an open-label extension where everyone could get the drug. The main goal was to see if camotes…
Phase 2 • Sponsor: Apollo Therapeutics Ltd • Aim: Disease control
Last updated Jun 26, 2026 17:44 UTC
-
AI boosts skin diagnosis accuracy in small trial
Diagnosis CompletedThis completed study tested whether an AI device could help 16 doctors (10 general practitioners and 6 dermatologists) more accurately diagnose 13 different skin conditions, including melanoma, psoriasis, and acne. The doctors reviewed 29 medical images, first giving a diagnosis …
Sponsor: AI Labs Group S.L • Aim: Diagnosis
Last updated Jun 27, 2026 09:07 UTC
-
New eczema drug ATTO-3712 enters early human safety trials
Symptom relief CompletedThis early-stage study tests a new drug called ATTO-3712 in healthy adults and people with atopic dermatitis (eczema). The main goal is to check if the drug is safe and how the body processes it. Participants receive either the drug or a placebo and are monitored with clinic visi…
Phase 1 • Sponsor: Attovia Therapeutics Inc • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
New cream offers hope for unbearable itch
Symptom relief CompletedThis Phase 3 trial tested a cream containing ruxolitinib in 204 adults with prurigo nodularis, a skin condition causing intense itching and hard bumps. Participants applied the cream twice daily for 12 weeks. The main goal was to see if it reduced itch by at least 4 points on a 0…
Phase 3 • Sponsor: Incyte Corporation • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
Which skin glue is gentler? new study puts three to the test
Symptom relief CompletedThis study tested three different skin glues (Dermabond, Swiftset, and Liquiband) used to close small incisions after laparoscopic or robotic abdominal surgery. 180 adults each received two different glues on opposite sides of their incisions. The main goal was to see which glue …
Phase 3 • Sponsor: The University of Texas Health Science Center, Houston • Aim: Symptom relief
Last updated Jun 28, 2026 00:00 UTC
-
Spray vs. ointment: which works better for incontinence rash?
Symptom relief CompletedThis study tested whether a silicone barrier spray works as well as a standard zinc oxide ointment for treating mild skin rash caused by incontinence in nursing home residents. Forty participants received one of the two treatments as part of a regular skin care routine. Researche…
Sponsor: Taoyuan Armed Forces General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
Simple skin care may shield kids from cancer drug side effects
Symptom relief CompletedThis study tested a preventive skin care routine in 14 children (ages 6 months to 18 years) with brain tumors who were receiving targeted therapy (BRAF, MEK, or Pan-RAF inhibitors). The goal was to see if gentle skin care and sun protection could reduce or prevent skin reactions …
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
Ear spray showdown: can ectoin soothe outer ear itch?
Symptom relief CompletedThis study looked at two ear sprays—Ectoin Ear Spray and Normison Ear Spray—to see how well they work and if they are safe for people with chronic itching and skin irritation of the outer ear canal. 60 adults took part in this real-world observation. The main goal was to check if…
Sponsor: Bitop AG • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
New pill for Kids' eczema itch shows promise in large trial
Symptom relief CompletedThis study tested whether a new oral medicine called TAU-284 (bepotastine besilate) can reduce itching in children aged 7 to 15 with atopic dermatitis (eczema). Over 300 children took either TAU-284 or an older medicine (ketotifen) twice daily for several weeks. The main goal was…
Phase 3 • Sponsor: Tanabe Pharma Corporation • Aim: Symptom relief
Last updated Jun 27, 2026 08:09 UTC
-
Itch-Busting cream shows promise for painful skin bumps
Symptom relief CompletedThis Phase 3 trial tested a cream called ruxolitinib (also known as Opzelura) in 190 adults with prurigo nodularis, a skin condition causing intense itching and hard bumps. Participants applied the cream twice daily for 12 weeks. The main goal was to see if it could reduce itch b…
Phase 3 • Sponsor: Incyte Corporation • Aim: Symptom relief
Last updated Jun 27, 2026 08:05 UTC
-
New eczema drug shows promise in early trial
Symptom relief CompletedThis early-stage study tested a new medicine called BMS-986326 in 64 adults with moderate-to-severe atopic dermatitis (eczema) who did not get enough relief from creams or needed stronger treatments. The main goal was to check the drug's safety and how the body processes it. Rese…
Phase 1 • Sponsor: Bristol-Myers Squibb • Aim: Symptom relief
Last updated Jun 27, 2026 08:02 UTC
-
Scientists track severe allergies to uncover hidden patterns
Knowledge-focused CompletedThis completed study followed 945 people, mostly children and young adults with severe eczema or related allergic conditions, along with their relatives. Researchers observed how these diseases progress over up to a year, using tests like allergy skin pricks, blood draws, and lun…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
Simple creams might fight aging inflammation
Knowledge-focused CompletedThis pilot study tests whether applying over-the-counter moisturizers (CeraVe or Vaseline) daily for 4 weeks can reduce inflammation in adults aged 70 and older with dry skin. Researchers will measure skin barrier function, blood markers of inflammation, and skin microbes. The ma…
Phase 4 • Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jul 16, 2026 00:00 UTC
-
New study aims to predict painful skin rash in hospital patients
Knowledge-focused CompletedThis study looked at 271 hospital patients with incontinence to find out which factors most strongly predict a common skin problem called incontinence-associated dermatitis (IAD). Researchers tracked things like age, stool consistency, and mobility, checking patients' skin daily.…
Sponsor: Örebro University, Sweden • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Skin deep: new study probes hidden signals in hidradenitis
Knowledge-focused CompletedThis study examined skin samples from 15 people with hidradenitis suppurativa (HS) and 15 healthy volunteers to measure certain genes and proteins linked to inflammation. The goal was to better understand what causes HS and find possible markers of disease severity. No treatment …
Sponsor: Trakya University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC